N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

Sponsor: Sanofi • ClinicalTrials.gov ID: NCT06958536

Registry updated: 2026-10-15
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This is a phase 2, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.

Interventions

  • brivekimig (Drug)
    Route of Administration: Subcutaneous
  • Placebo (Drug)
    Route of Administration: Subcutaneous

Eligibility criteria

Inclusion Criteria: * Diagnosis of Crohn's Disease (CD) for at least 3 months prior to screening * Confirmed diagnosis of moderate-to-severe CD * History of prior exposure to standard treatment and having inadequate response to, loss of response to or intolerance to standard therapy with any of the following compounds: (5-Amino Salicylates (5-ASAs), 6-Mercaptopurine (6-MP), Azathioprine (AZA), Methotrexate (MTX), oral or corticosteroids or advanced therapies (ATs) (biologics or small molecules), but having inadequate response to, loss or response to or intolerance to at least one of these therapies * On stable doses of standard treatments prior to screening (Oral 5-ASA compounds, Oral corticosteroids, AZA, 6-MP, or MTX, or Antibiotics, etc.) * Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies Exclusion Criteria: * Participants with active Ulcerative Colitis (UC), indeterminate colitis, adenomatous colonic polyps not excised, colonic mucosal dysplasia (low- or high-grade dysplasia) or short bowel syndrome * Participants with CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic or ileal involvement * Participants with following ongoing known complications of CD: * Any manifestation that might require bowel surgery while enrolled in the study * Participant with ostomy or ileoanal pouch * Participant diagnosed with conditions that could interfere with drug absorption including but not limited to short bowel syndrome * Participant with surgical bowel resection within the past three months prior to screening, or a history of \>3 bowel resections * History of any other condition which, in the opinion of the Investigator, would put the participant at risk by participation in the study The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Conditions

Crohn's Disease

Locations

  • Investigational Site Number: 8400024 — Tucson, Arizona, United States
  • Investigational Site Number: 8400005 — Escondido, California, United States
  • Investigational Site Number: 8400001 — Lancaster, California, United States
  • Investigational Site Number: 8400017 — Kissimmee, Florida, United States
  • Investigational Site Number: 8400015 — Lighthouse PT, Florida, United States
  • Investigational Site Number 8400028 — Miami, Florida, United States
  • Investigational Site Number: 8400012 — Miami, Florida, United States
  • Investigational Site Number: 8400007 — Orlando, Florida, United States
  • Investigational Site Number: 8400011 — Palmetto Bay, Florida, United States
  • Investigational Site Number: 8400019 — Marietta, Georgia, United States
  • Investigational Site Number: 8400025 — Iowa City, Iowa, United States
  • Investigational Site Number: 8400006 — Kansas City, Kansas, United States
  • Investigational Site Number: 8400022 — Boston, Massachusetts, United States
  • Investigational Site Number: 8400008 — Wyoming, Michigan, United States
  • Investigational Site Number: 8400013 — St Louis, Missouri, United States
  • Investigational Site Number: 8400003 — Chapel Hill, North Carolina, United States
  • Investigational Site Number: 8400009 — Harrisburg, Pennsylvania, United States
  • Investigational Site Number: 8400002 — Fredericksburg, Texas, United States
  • Investigational Site Number: 8400016 — Ogden, Utah, United States
  • Investigational Site Number: 8400027 — Richmond, Virginia, United States
  • Investigational Site Number: 0360002 — Brisbane, Queensland, Australia
  • Investigational Site Number: 0360004 — Kurralta Park, South Australia, Australia
  • Investigational Site Number: 0360001 — Footscray, Australia
  • Investigational Site Number: 0560001 — Leuven, Belgium
  • Investigative Site: 1560003 — Changsha, China
  • Investigational Site Number: 1560008 — Changsha, China
  • Investigative Site: 1560005 — Changzhou, China
  • Investigational Site Number: 1560001 — Guangzhou, China
  • Investigational Site Number: 1560006 — Hangzhou, China
  • Investigative Site: 1560004 — Nanchang, China
  • Investigative Site: 1560002 — Shanghai, China
  • Investigational Site Number: 1560007 — Shenyang, China
  • Investigational Site Number: 2030002 — Brno, JM, Czechia
  • Investigational Site Number: 2030003 — Hradec Králové, Czechia
  • Investigational Site Number: 2030005 — Slaný, Czechia
  • Investigational Site Number: 2500001 — Montpellier, France
  • Investigational Site Number: 2500003 — Nice, France
  • Investigational Site Number: 2500002 — Toulouse, France
  • Investigational Site Number: 2760002 — Minden, Northwest, Germany
  • Investigational Site Number: 2760003 — Jena, Germany
  • Investigational Site Number: 2760004 — Kiel, Germany
  • Investigational Site Number: 2760001 — Ulm, Germany
  • Investigational Site Number: 3920007 — Kashiwa, Chiba, Japan
  • Investigational Site Number: 3920005 — Ōita, Oita Prefecture, Japan
  • Investigational Site Number: 3920006 — Hamamatsu, Shizuoka, Japan
  • Investigational Site Number: 3920004 — Bunkyō City, Japan
  • Investigational Site Number: 3920003 — Hamamatsu, Japan
  • Investigational Site Number: 3920009 — Hirosaki, Japan
  • Investigational Site Number: 3920001 — Morioka, Japan
  • Investigational Site Number: 3920002 — Nishinomiya, Japan
  • Investigational Site Number: 6160002 — Wroclaw, Lower Silesian Voivodeship, Poland
  • Investigational Site Number: 6160001 — Krakow, Poland
  • Investigational Site Number: 6160005 — Lublin, Poland
  • Investigational Site Number: 6160006 — Sopot, Poland
  • Investigational Site Number: 6160008 — Warsaw, Poland
  • Investigational Site Number: 6160003 — Warsaw, Poland
  • Investigational Site Number: 6160004 — Wroclaw, Poland
  • Investigational Site Number: 7100003 — Johannesburg, South Africa
  • Investigational Site Number: 7240002 — Madrid, Spain
  • Investigational Site Number: 7240001 — Madrid, Spain
  • Investigational Site Number: 7240003 — Seville, Spain
  • Investigational Site Number: 8260007 — Bury, United Kingdom
  • Investigational Site Number: 8260004 — Cambridge, United Kingdom
  • Investigational Site Number: 8260005 — London, United Kingdom
  • Investigational Site Number: 8260002 — London, United Kingdom
  • Investigational Site Number: 8260001 — London, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record